Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of Chronocort versus standard glucocorticoid replacement therapy in adults with congenital adrenal hyperplasia
NL-OMON46149Phase 3Active, not recruiting
- Sponsor
- MediServ
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydrocortisone modified-release in congenital adrenal hyperplasia (CAH), sponsored by MediServ. Primary endpoint: Superior efficacy based on 17-hydroxyprogesterone. Started Jul 2016; status: active, not recruiting.
02
Drugs
hydrocortisone modified-release
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NL-OMON46149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46149.